

**HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC)
 NICE TECHNOLOGY APPRAISALS – RECOMMENDED**

**NICE TA 292: ARIPIPRAZOLE FOR TREATING MODERATE TO SEVERE
 MANIC EPISODES IN ADOLESCENTS WITH BIPOLAR I DISORDER,
 July 2013
RESTRICTED RECOMMENDATION**

Names: generic (trade)	What it is	Indication	Date decision last revised	Decision status	NICE guidance
Aripiprazole (Abilify®)	Antipsychotic (second generation)	For the treatment up to 12 weeks of moderate to severe manic episodes in bipolar I disorder in adolescents aged 13 and older	September 2013	Final	NICE TA 292 - recommended

HMMC Recommendation:

RECOMMENDED for initiation and continuation of prescribing by specialists only for adolescent patients with bipolar I disorder in line with NICE TA292.

NOT RECOMMENDED for prescribing in primary care for adolescent patients with bipolar I disorder.

NICE Recommendation:

1.1 Aripiprazole is recommended as an option for treating moderate to severe manic episodes in adolescents with bipolar I disorder, within its marketing authorisation (that is, up to 12 weeks of treatment for moderate to severe manic episodes in bipolar I disorder in adolescents aged 13 and older).

Patient numbers for this group are small and HPFT CAMHS (Child and Adolescent Mental Health Services) specialists have confirmed that the prescribing responsibility for this short term treatment will remain with their service.

It is therefore recommended that GPs do not accept prescribing responsibility for this short-term specialised treatment in this patient group.

Reference: NICE TA 292 - Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder, July 2013 <http://guidance.nice.org.uk/TA292>

**Produced by Hertfordshire Pharmacy and Medicines Optimisation Team
 Hertfordshire, Bedfordshire and Luton Commissioning Support
 NHS Central Eastern Commissioning Support Unit**